Evidence map›Paper›PMID 33235069›Full record

Observational studyMedicine2020

Defining prognosis in sarcoidosis.

Mariana Carneiro Lopes, Thaís Porto Amadeu, Marcelo Ribeiro-Alves, Claudia Henrique da Costa, Bruno Rangel Antunes Silva, Luciana Silva Rodrigues, Elisabeth Jauhar Cardoso Bessa, Leonardo Palermo Bruno, Agnaldo José Lopes, Rogerio Rufino

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Prognostic impact ofBMC pulmonary medicine · 2026
    Article
  4. Article
  5. The DSC Index: A new prognostic tool for evaluating functional status in interstitial lung disease.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Mariana Carneiro LopesDepartment of Thoracic Disease.
Thaís Porto AmadeuDepartment of Pathology and Laboratories, State University of Rio de Janeiro.
Marcelo Ribeiro-AlvesNational Institute of Infectology Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Claudia Henrique da CostaDepartment of Thoracic Disease.
Bruno Rangel Antunes SilvaDepartment of Thoracic Disease.
Luciana Silva RodriguesDepartment of Pathology and Laboratories, State University of Rio de Janeiro.
Elisabeth Jauhar Cardoso BessaDepartment of Thoracic Disease.
Leonardo Palermo BrunoDepartment of Thoracic Disease.
Agnaldo José LopesDepartment of Thoracic Disease.
Rogerio RufinoDepartment of Thoracic Disease.
Universidade do Estado do Rio de Janeiro · BRInstituto Evandro Chagas · BRS.P.E.C.I.E.S. · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcoidosis is a multi-systemic granulomatous disease. Affected individuals can show spontaneous healing, develop remission with drug treatment within 2 years, or become chronically ill. Our main goal was to identify features that are related to prognosis.The study consisted of 101 patients, recruited at a single center, who were already diagnosed with sarcoidosis at the start of the study or were diagnosed within 48 months. Ninety individuals were followed-up for at least 24 months and were classified according to clinical outcome status (COS 1 to 9). Those with COS 1-4 and COS 5-9 were classified as having favorable and unfavorable outcomes, respectively. Unconditional logistic regression analyses were conducted to define which variables were associated with sarcoidosis outcomes. Subsequently, we established a scoring system to help predict the likelihood of a favorable or unfavorable outcome.Of our patients, 48% developed a chronic form of the disease (COS 5-9). Three clinical features were predictive of prognosis in sarcoidosis. We built a score-based model where the absence of rheumatological markers (1 point), normal pulmonary functions (2 points), and the presence of early respiratory symptoms manifestations (2 points) were associated with a favorable prognosis. We predicted that a patient with a score of 5 had an 86% (95% confidence interval [CI] 74%-98%) probability of having a favorable prognosis, while those with scores of 4, 3, 2, 1, and 0 had probabilities of 72% (95% CI 59-85%), 52% (95% CI 40-63%), 31% (95% CI 17-44%), 15% (95% CI 2-28%), and 7% (95% CI 0-16%) of having a favorable prognosis, respectively. Thus, our easy-to-compute algorithm can help to predict prognosis of sarcoidosis patients, facilitating their management.

Indexed as

AdultAlgorithmsBrazilCohort StudiesFemaleHumansMaleMiddle AgedPrognosisSarcoidosis

Identifiers

PMID33235069
PMCPMC7710206
OpenAlexW3108906709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.